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Abstract
Multiple Sclerosis (MS) is an autoimmune inflammatory disorder of the Central 
Nervous System (CNS), affecting more than one million people worldwide. The 
pathogenesis of MS involves several genetic and environmental factors, which 
ultimately lead to the activation of autoreactive T cells in the periphery, their 
migration into the CNS, where they trigger an acute inflammatory response, 
thus mediating primary demyelination and axonal damage. Most information 
on MS derives from studies in animal models of experimental autoimmune 
encephalomyelitis (EAE), which exhibit many similarities to the pathology of 
MS. Two distinct subsets of autoreactive T cells have been primarily involved in 
the pathogenesis of both EAE and MS: the interferon (IFN)-γ producing CD4+ T 
helper (Th) 1 and interleukin (IL)-17 producing Th17 cells. The activity of these 
cells is controlled by specific regulatory T cells (Treg), which by secreting anti-
inflammatory cytokines such as IL-4, IL-10 and tumour growth factor (TGF)-β 
efficiently inhibit Th1 and Th17 cells.
In this review, we summarize current knowledge on the role and function of 
pro-inflammatory and Treg subsets in MS. We also discuss the action of current 
and novel therapies aimed to dampen inflammatory T cells.
Keywords: Multiple sclerosis; Inflammatory T cells; Regulatory T cells; 
Therapy; Costimulation
brain barrier (BBB) integrity, recruiting immune cells from the 
periphery, and activating resident microglia. Conversion of MS 
from RR to progressive phases has been related to prolonged chronic 
inflammation in the CNS. Moreover, both SPMS and PPMS patients 
have generalized inflammation in the whole brain accompanied by 
cortical demyelination and diffuse white matter injury [4].
Although several cell types within the CNS may contribute to the 
production of pro-inflammatory cytokines and chemokines, activated 
autoreactive T cells have a key role in inflammatory demyelination 
[5]. Indeed, the cytokine and chemokine-producing phenotype of 
self-reactive T cells in MS patients determines the ability of these cells 
to cross BBB and cause inflammation in the CNS, thus contributing 
to disease progression.
This article reviews the current knowledge on the contribution of 
different T cell subsets in the pathogenesis of MS and discusses the 
current and novel therapeutic strategies, which aim to dampen the 
pathogenic inflammatory T-cell response.
Inflammatory T helper cell subsets in MS: Th1 and Th17 
cells
The more accepted pathogenic model for both EAE and MS is 
that autoreactive myelin-specific CD4+ T cells are activated in the 
periphery, entered the CNS by crossing the BBB and are reactivated 
by resident antigen-presenting cells (APC), mainly of which is 
microglial cells [5,6]. The priming and activation of autoreactive 
myelin-specific CD4+ T cells likely occurs in peripheral lymph nodes, 
where the dendritic cells (DC) may present myelin epitopes to naive T 
cells, thus inducing the activation and differentiation of autoreactive 
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Introduction
MS is an autoimmune chronic inflammatory disorder 
characterized by demyelination and remyelination events and by 
the loss of sensory and motor functions. Two third of MS patients 
present the relapsing-remitting (RR) course, which is characterized 
by relapses usually followed by periods of recovery or remission, but 
one third of patients progresses to chronic secondary progressive 
(SP) disease [1,2]. A minority of patients (10-20%) experiences 
a primary progressive disease (PP), which is characterized by a 
gradual and constant decline in their neurological functions from 
the onset of disease [3]. Inflammation is present at all stages of MS 
[4] and pro-inflammatory cytokines/chemokines play a critical 
role in the pathophysiology of MS by compromising the blood-
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effector/memory T helper cells, which in turn migrate to the CNS and 
cause tissue damage and demyelination. Several evidences support 
a function for myelin proteins, such as MBP (myelin basic protein), 
PLP (proteolipid protein) and MOG (myelin oligodendrocyte 
glycoprotein), as relevant antigens in both EAE and MS [7-11]. In 
EAE, myelin-specific T cell responses seem to initiate in the CNS-
draining cervical lymph nodes, thus suggesting that myelin proteins 
are constitutively presents in some lymph nodes [12]. Moreover, 
high avidity myelin-specific CD4+ T cells have been isolated from the 
periphery of MS patients [13,14].
It has been thought for a long time that the pathogenetic cells 
mediating MS were CD4+ Th1 cells, producing large quantity of 
IFN-γ driven by IL-12 [15,16]. Indeed, IFN-γ-deficient mice as well as 
knockout mice for IL-12p40, the large subunit of IL-12, were resistant 
to EAE [17-20]. However, further observations that mice deficient in 
IL-12p35, the smaller subunit of IL-12, and IL-12Rβ2 were susceptible 
to EAE [21,22] as well as data showing that the administration of 
IL-12 during the early phases of EAE suppressed EAE in an IFN-γ 
dependent manner [23], suggested that Th1 cells could not be 
responsible for the pathogenesis of MS. The discovery that IL-23 
shares the p40 subunit with IL-12 clarifies these contradictory data 
[24]. Cua et al. demonstrated that IL-23 rather than IL-12 is crucial 
for EAE development by showing that IL-23p19, the smaller subunit 
of IL-23, deficient mice were resistant to EAE [25,26]. Data from 
Langrish et al. clearly defined the role of IL-23 in favouring EAE by 
driving and inducing the expansion of a novel Th subset producing 
IL-17 [26], designated Th17 cells [27,28].
The hallmark of Th17 cells is the production of the pro-
inflammatory cytokine IL-17 (A and F) that affects the functions of a 
wide range of cells, enhances the secretion of other pro-inflammatory 
cytokines and chemokines and increases the activation of matrix 
metalloproteinases, thus contributing to the breakdown of BBB [29]. 
In the human system, Th17 differentiation can be mediated by IL-
6, TGF-β and IL-21, while IL-23 is critical in maintaining the Th17 
phenotype [30-35]. Several data demonstrated that CD4+ Th17 
subset exerts a central role in the pathogenesis of both EAE and 
MS. Increased numbers of Th17 cells have been found in the both 
inflamed CNS [36] and in the periphery of acute EAE [5] as well as 
in the CSF of MS patients during relapses [37]. High levels of IL-17A 
have been also detected in circulating leukocytes of MS patients with 
active disease [38], and higher IL-17A production has been correlated 
with the number of active plaques on magnetic resonance imaging 
[39]. All these data strongly support a pivotal contribution of Th17 
cells in the pathology of MS [40].
Regulatory T cells (Tregs)
Tregs are negative regulators of T helper cell responses and 
contribute to T cell “anergy” and to the maintenance of self- tolerance, 
thus protecting against autoimmunity [41,42]. Tregs can be identified 
through their surface phenotypes and cytokine producing profiles. 
Tregs may be divided into two main subsets, natural Tregs (nTregs) 
and inducible Tregs (iTregs). The CD4+CD25+ FOXP3+ nTregs 
develop in the thymus and their TCR repertoire is skewed towards 
the recognition of self-antigens. In contrast, iTregs, originate from 
naive T cells in the peripheral lymph nodes, are either CD4+ or CD8+ 
and may or not express FOXP3 [43].
Dysfunctions or impairment maturation of Tregs have been 
observed in animal models of MS [44]. The presence of myelin-
specific Tregs within the CNS during EAE highlights their role in the 
control of disease. Indeed, the accumulation and frequency of Tregs 
in the CNS has consistently been shown to correlate with recovery 
from EAE. However, myelin-specific Tregs were not sufficient to 
reduce the function of encephalitogenic effector T cells during the 
peak of EAE [45].
In MS, several reports have shown that human Tregs are 
functionally impaired, have decreased FOXP3 expression compared 
to healthy individuals, or have deficit in their maturation, or in their 
thymic emigration [44]. Reduced number or impaired suppressive 
functions of Tregs have been also found in the peripheral blood of 
MS patients [46-49]. Therefore, dysfunction in the number and/or 
functions of Tregs may concur to the immunopathogenesis of MS 
by decreasing the suppression of activated pathogenic immune cells 
(Figure 1).
T-cell based therapeutic strategies
Our understanding of the key role of T cells in MS has led to a 
vast research during the last two decades in an attempt to develop 
novel therapeutic strategies for T-cell immunotherapy. Below are 
summarized some that are currently used and others that required 
further studies.
First-line treatments: IFN-β and glatiramer acetate (GA)
The most common disease modifying drugs used in the first-line 
treatment of RRMS include IFN-β or GA. Although the mechanisms 
of action of these compounds are still poorly understood, they exert 
some effects on T lymphocytes.
IFN-β belongs to a family of cytokines, which interfere with 
virus replication and exhibit immunomodulatory activities. In 1981, 
the administration of IFN-β to MS patients resulted in a significant 
reduction of the relapse rate [50], thus encouraging further clinical 
trials [51]. IFN-β is actually approved as first-line therapy for RRMS, 
SPMS with additional relapses in the European Union (EU) [52], 
Figure 1: CD4+ Th cell subsets in MS. Naive CD4+ T cells are activated 
in peripheral lymp nodes by myelin-like peptide presented on dendritic cells 
(DC). Specific cytokines direct the polarization of activated Th cells into Th1 
(IL-12, INF-γ), Th17 (IL-6 and TGF-β) of Treg cell subsets (TGF-β). Activated 
Th cells leave the limph nodes and migrate into the CNS across the BBB. 
In the CNS, Th cells interact with resident microglia, are reactivated upon 
recognition of myelin antigens and produce cytokines and chemokines that 
lead (Th1 and Th17) or suppress (treg) the inflammatory cascade in the CNS 
and damage.
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but not for PPMS patients, who showed no significant reduction of 
disability after treatment [53].
The immunomodulatory activities of IFN-β in ameliorating 
RRMS include its ability to interfere with T cell activation by 
inhibiting the up-regulation of MHC class II molecules induced 
by IFN-γ on APC [54] as well as to inhibit costimulatory molecule 
functions (i.e. CD40/CD40L and CD28/B7) [55,56]. More recently, 
the immunosuppressive effects of IFN-β were related to immune 
deviation. Distinct reports showed that IFN-β treatment impairs 
Th17 cells by reducing IL-23 levels and up-regulating IL-10, which 
has general suppressive effects on Th cells or by inducing IL-27, which 
inhibits Th17 cell differentiation [57-59]. A role of IFN-β in inducing 
Tregs has also been evidenced [60,61]. In a longitudinal follow-
up stadium performed on stable RRMS patients before and after 
6-months of IFN-β therapy, Namdar et al. evidenced a significant 
increase of both frequency and suppressive functions of Treg cells of 
IFN-β- treated patients [61]. Increased frequency of Treg cells was 
also observed in EAE mice after IFN-β treatment. This event seems 
to be correlated to enhanced proliferation of Treg cells mediated by 
the up-regulation of glucocorticoid- induced TNF receptor ligand 
(GITRL) on the surface of dendritic cells [60].
Besides the beneficial effects of IFN-β in MS, common side effects 
have been reported, which include flu-like symptoms, injection-
side reactions (i.e. pain, swelling, lypoatrophy), lymphocytopenia 
and elevated liver enzymes. Moreover, a significant proportion of 
MS patients (between 7 % to 49%) do not respond to IFN-β [62]. 
One of the main causes of IFN-β treatment failure is related to the 
development of neutralizing anti-IFN-β antibodies [63].
GA is a copolymer of alanine, lysine glutamic acid and tyrosine that 
exerts multiple immunomodulatory activities. Its immunosuppressive 
effects on Th cells has been related to the inhibition of IFN-γ and 
stimulation of IL-4 secretions, thus favouring a shift of the immune 
response from pro-inflammatory Th1 to anti-inflammatory Th2 
[64,65]. Another mechanism of the anti-inflammatory effects of GA is 
the expansion of Tregs through the up-regulation of FOXP3 [66,67]. 
However, beneficial effects of GA administration were demonstrated 
only in RRMS [68,69].
In summary, the mechanisms of action of either IFN-β or GA 
partly target T-cell mediated inflammatory response in MS. However, 
both drugs often fail to exhibit sufficient clinical effectiveness and have 
very little effects in progressive phases of the disease that is currently 
treated with mitoxantrone, an immunosuppressive cytotoxic drug 
with immunomodulatory activity, but with serious side effects, such 
as myelosuppression and cardiac toxicity (Table 1) [70-72].
Second-line therapeutic drugs
Second-line drugs, commonly used in case of failure or intolerance 
to the first-line therapeutic agents, include natalizumab, fingolimod 
and cladribine. Generally, these agents are more potent than those 
used in the first-line therapy, but exhibit potential adverse side effects 
(ASEs) [73,74].
Natalizumab is a humanized recombinant monoclonal antibody 
directed against the α4 subunit of α4β1 and α4β7 integrins expressed on 
lymphocytes. In particular, the integrin a4b1 binds to the vascular-cell 
adhesion molecule (VCAM)-1 on endothelial cells of brain and spinal 
cord vessels, thus allowing immune cells to cross BBB. Natalizumab 
prevents the migration of lymphocytes into the CNS [75]. In humans, 
natalizumab strongly reduces the numbers of CD4+ T lymphocytes in 
the CNS [76]. The results obtained by both AFFIRM and SENTINEL 
clinical trials demonstrated a strong reduction of both the annualized 
relapse rate and disability progression in natalizumab-treated RRMS 
patients [77,78]. However, it may induce severe secondary effects 
[74,77,79] and clinical complications such as progressive multifocal 
leukoencephalopathy by polioma JC virus [80].
Fingolimod (FTY720) binds to sphingosine-1-phosphate 
receptors (S1PR) and blocks the egress of both T and B cells from 
secondary lymphoid organs into circulation. Moreover, due to its 
lipophilic properties, fingolimod may cross the BBB and by binding the 
S1PR expressed on astrocytes, oligodendrocytes and microglia, may 
promote their survival and favour remyelination [81,82]. The results 
obtained by both TRANSFORMS [83] and FREEDOMS [84] clinical 
trials showed a strong reduction in both relapses and accumulation 
of new or enlarging T2 lesions. Moreover, the availability of oral 
active forms of fingolimod may also circumvent the ASEs (e.g. skin 
indurations and lipoatrophy) related to infusion or injection and may 
exhibit higher adherence and long-term persistence [85]. However, 
important ASEs, including infections, arrhythmias, hypertension, 
macula edema as well as serious ASEs, such as asystole, bradycardia 
and malignant neoplasm have been reported [83,84,86,87]. More 
recently, an observational study by Carruthers et al. aimed to compare 
the effectiveness of natalizumab and fingolimod in clinical practice 
evidenced the superior effectiveness of natalizumab [88]. Thus, a 
deeper assessment of the effectiveness, safety and adherence during a 
long-term period of treatment should be required be required.
Cladribine is a synthetic deoxyadenosine analogue used as an oral 
immunomodulatory drug in the treatment of chronic progressive 
MS patients [89-91]. Cladibrine targets lymphocytes resulting 
in sustained reduction of peripheral T and B lymphocytes. The 
administration of oral cladribine resulted in reducing relapse-rates 
and disability progression in patients with RRMS [92-95]. Despite the 
strong lymphopenia observed in patients treated with oral cladibrine, 
no significant differences in the overall incidence of infections were 
observed. However, herpes zoster infections as well as neoplasm 
occurred in cladribine-treated patients, thus suggesting further 
monitoring to weigh the benefits against potential risks.
Other anti-inflammatory drugs are approved as second line-line 
therapy (Table 1). However, most of these non-specific therapeutic 
strategies compromise the ability of T cells to fight infections or to 
control cancer development and progression, thus more studies 
are required to determine the most efficacious, safe and tolerable 
treatment.
Targeting specific surface molecules or soluble cytokines 
for dampening inflammatory T cells in MS 
Other therapies in clinical trials include the use of specific 
antibodies (Abs) targeting T cells or pro-inflammatory cytokines.
Daclizumab is a humanized monoclonal Ab directed against 
CD25. CD25 is the alpha chain of the high affinity IL-2 receptor. CD25 
is up-regulated on activated T cells and is necessary for IL-2-driven 
survival and proliferation of activated T cells, including autoreactive 
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cells. Binding of daclizumab to CD25 blocks the survival and 
proliferation of activated T cells through the preferential expansion 
of regulatory CD16-CD56bright natural killer (NK) cells with anti- viral 
and anti-tumour activities [96,97]. In phase III trials, daclizumab 
resulted in a significant reduction of the relapse rate and disability 
progression by more than 50% [98]. However, the ASEs reported in 
both phase II and III clinical trials were higher rate of infections, skin 
disorders, diffuse lymphadenopathy, and elevated liver enzymes [98-
100].
Alemtuzumab is a humanized monoclonal Ab against CD52, a 
surface glycoprotein expressed on several immune cells including T 
and B cells, eosinophils and monocytes. Its selective expression on 
mature cells but not on lymphoid progenitors made it a good target for 
immunotherapy [101]. The interaction of alemtuzumab with CD52 
leads to the depletion of CD52+ cells [102], through complement and/
or cell mediated lysis [103]. Data from clinical trials evidenced a strong 
reduction of relapses and neurological disability in RRMS patients 
[104,105]. However, given the prolonged immunosuppression 
after treatment with alemtuzumab, its impressive effectiveness was 
associated with a high risk of thyroid autoimmune diseases [106]. 
Thus, the drug was not approved by the FDA due the negative risk/
benefit ratio but is currently approved in Europe (Table 1).
Despite the encouraging data obtained by the administration 
of neutralizing anti-IL-12 or anti-IL23p19 monoclonal Abs in EAE 
[107-109], treatment of RRMS patients with IL-12/23p40 neutralizing 
monoclonal Ab (ustekinumab) did not result in any significant 
therapeutic benefits in a phase II trial [110].
CD28/B7 costimulatory molecules as therapeutic targets
Optimal priming and activation of CD4+ T cells requires T cell 
receptor (TCR)-recognition of peptide-MHC class II complexes 
together with signals delivered by costimulatory molecules expressed 
on the surface of professional APCs. CD28 is constitutively expressed 
on 90% of naive and activated CD4+ T cells and on 50% of CD8+ T 
cells. By binding its cognate ligands B7.1/CD80 or B7.2/CD86 on the 
surface of professional APCs, CD28 lowers TCR activation threshold, 
thus leading to the augmentation of early signalling events necessary 
for efficient cytokine production, cell cycle progression and survival. 
Furthermore, CD28 ligation enhances the expression of CD40L 
and adhesion molecules necessary for trafficking, such as VLA-4. 
Moreover, CD28 is able to emanate TCR-independent autonomous 
signals, which account for its critical role in the regulation of pro-
inflammatory cytokine/chemokine [111,112] and Th17 amplification 
in MS [113].
Another function of CD28 is its involvement in the development 
and homeostasis of Tregs. CD28 is required for both efficient 
generation of Tregs in the thymus [114] and for limiting T cell 
activation by sustaining the survival of Tregs in the periphery [115]. 
These evidences support the hypothesis that the presence of B7, even 
on cells that are not displaying the cognate antigen, may control 
adaptive immune responses [116]. Therefore, CD28 deficiency 
can lead to a reduced disease potential as well as to an enhanced 
susceptibility to autoimmune diseases by altering T cell effector 
and Tregs compartments, thus representing an interesting target to 
ameliorate cell dysfunctions in autoimmune diseases.
All CNS-infiltrating mononuclear cells in EAE, including CD4+ 
T cells, express CD80/B7.1 [117,118]. However, conflicting and 
opposing results have been obtained by using CTLA4-Ig or anti-B7 
antibodies on EAE mice. Although, CTLA-Ig efficiently inhibits 
TCR-induced activation of autoreactive T cells by blocking CD28/
Drug Mode of action
Approved in 
Europe
Major side-effects
IFN-β
Immunomodulation:
- Reduction of Il-23 and upregulation of IL-10 levels
- Expansion of Tregs
- RRMS (first-line)
- SPMS with 
relapses
- Flu-like symptoms
- Injection-side  reactions
- Hepatotoxicity
Glatiramer acetate 
(GA)
Immunodulation:
- Reduction of IFN-γ (Th1) and up-regulation of IL-4 
(Th2)
- Expansion of Tregs
- RRMS (firs-line)
- Flu-like symptoms
- Injection-side reactions (lipoatrophy)
Dimethyl-fumarate
Immunomodulation:
- Depletion of peripheral blood T cells
- Reduction of IFN-γ (Th1) and up-regulation of IL-4 
(Th2)
- RRMS (first-line)
- Flushing
- Gastrointestinal side effects
- Hepatotoxicity
- Leukopenia
Terifluoomide Inhibition  of  proliferation of active dividing cells - RRMS (first-line)
- Gastrointestinal side effects
- Hair loss
- Hepatotoxicity
- Leukopenia
- Teratogenic potential
Natalizumab
Blocking migration of immune 
cells to the CNS
- RRMS (second-
line)
- Allergic infusion reactions
- Infections (PML)
- Hepatotoxicity
Fingolimod Blocking egress of lymphocytes from lymph nodes
- RRMS (second-
line)
- Infections (HSV, VZV)
- Bradycardia and arrythmias
- Macular edema
Alemtuzumab
Depletion of immune cells expressing CD52 (i.e. 
T cells)
- RRMS (highly 
active)
- Allergic infusion reactions
- Infections (HSV)
- Autoimmune disorders (thyroid and Good-pasture 
syndrome)
Mitoxantrone Inhibition  of  proliferation of active dividing cells
- RRMS (highly 
active)
- SPMS
- Cardiotoxicity
- Gastrointestinal side effects
- Acute myeloid leukemia
Table 1: Currently approved therapies in MS.
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B7 interaction, it cross-links CD80 expressed on either APCs or 
activated autoreactive T cells, thus inducing IFN-γ production and 
contributing to the disease exacerbation [119]. Moreover, several 
studies evidenced that peripheral myelin-reactive T cells from MS 
patients are primarily effector/memory T cells in a higher activation 
state, which express high avidity TCRs and are less dependent from 
CD28/B7 costimulation in terms of TCR-activation [120].
Blockade of CD28/B7 interaction by recombinant CTLA4-Ig 
(adaptacept), which binds B7.1/B7.2 with high affinity, is being 
evaluated in RRMS in both phase I [121] and phase II clinical trials 
(ClinicalTrials.gov, identifier: NCT01116427).
More recently, anti-CD28 superagonistic Abs have been 
successfully used to inhibit the onset, progression and clinical 
course of EAE, by preferentially activating and expanding the 
immunosuppressive Tregs [122]. However, when administered to 
volunteers in phase I clinical trial, a humanized CD28 superagonistic 
Ab (TGN1412) induced a rapid and massive production of pro-
inflammatory cytokines (i.e. IFN-γ and TNF-α), thus causing a severe 
systemic inflammatory response syndrome [123]. Moreover, our 
group has recently observed that the human superagonistic CD28 
ANC28.1 Ab strongly up-regulated CD4+CD25highFOXP3+ Tregs at a 
similar extent in RRMS patients and healthy donors [113].
These data arise, at least, two important considerations: 1) CD28 
signals can mediate different functions depending on the presence 
or not of TCR co-engagement and 2) the translation of experimental 
results from mice to men could determine dramatic effects, 
supporting differences in CD28 functions and signalling capability 
between humans and mice. Thus, the blockage of CD28 signalling, 
rather than its stimulation, may have heuristic implication for the 
development of more efficient therapies in MS.
CD28-associated PI3K signalling pathway as a potential 
therapeutic target
Phosphatidylinositol-3 kinase (PI3K) is a critical mediator of 
CD28 signalling [124]. The intracytoplasmic tails of CD28 binds and 
activates class 1 PI3K that phosphorylates inositol phospholipids 
on carbon atom 3, thus generating the phosphatidylinositol 
3,4-biphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate 
(PIP3) [112,125]. PIP2 and PIP3 lipids bind the pleckstrin domains of 
several molecules involved in CD28 signals, in particular the protein 
kinase B/Akt [126,127], thus affecting both the fate and movement 
through the body of T cells [128,129].
The PI3K/Akt pathway plays a central role in regulating 
inflammation and abnormalities in this pathway could be linked to the 
development of autoimmunity [130]. The activity of the PI3K network 
can be manipulated by pharmacological compounds, several of which 
are approved for clinical use in some inflammatory and autoimmune 
diseases. Blockage of class I PI3Kγ subunit has resulted effective in 
reducing both disease severity and incidence in a mouse model of 
systemic lupus erythematosus [131] and the delivery of oral active 
form of PI3Kγ inhibitor AS-605240 reduces joint inflammation and 
cartilage erosion in mouse models of rheumatoid arthritis [132,133].
Our recent results on the ability of AS-605240 to inhibit the pro-
inflammatory responses induced by CD28 stimulation in RRMS, 
suggest PI3K as a valuable therapeutic candidate for MS. Moreover, 
the availability of oral active forms of PI3K inhibitors [134] may 
also circumvent the ASEs (e.g. skin indurations and lipoatrophy) 
related to infusion or injection and may exhibit higher adherence and 
long-term persistence, as observed for other oral compounds (e.g. 
fingolimod) [85].
Conclusion
Inflammatory T cells have a well recognized role in the 
pathogenesis of MS. Most of the current therapeutic strategies 
focus on blocking the pro-inflammatory responses in a non-specific 
manner, thus compromising the ability of T cells to fight infections 
or to control cancer. From basic researches and pre-clinical findings 
in animal model, a growing number of therapeutic agents are 
upcoming. A future challenge will be to identify the most efficacious, 
safe and tolerable anti- inflammatory drugs that used in combination 
with treatments that block neurodegeneration may also favour 
remyelination and tissue repair.
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